Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Clinical Trials as Topic; Drug Repositioning; Host-Pathogen Interactions/drug effects; SARS-CoV-2/drug effects; Adenosine Monophosphate/administration & dosage; Adenosine Monophosphate/analogs & derivatives; Adenosine Monophosphate/therapeutic use; Administration, Oral; Alanine/administration & dosage; Alanine/analogs & derivatives; Alanine/therapeutic use; Animals; Anti-Inflammatory Agents/administration & dosage; Anti-Inflammatory Agents/therapeutic use; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/therapeutic use; Antibodies, Neutralizing/administration & dosage; Antibodies, Neutralizing/economics; Antibodies, Neutralizing/therapeutic use; Antiviral Agents/administration & dosage; Antiviral Agents/pharmacology; COVID-19/economics; COVID-19/immunology; COVID-19/mortality; COVID-19/virology; COVID-19 Vaccines; Cytidine/analogs & derivatives; Cytidine/therapeutic use; Depsipeptides/pharmacology; Depsipeptides/therapeutic use; Dexamethasone/administration & dosage; Dexamethasone/therapeutic use; Drug Combinations; Drug Synergism; Esters/pharmacology; Esters/therapeutic use; Guanidines/pharmacology; Guanidines/therapeutic use; Hospitalization; Humans; Hydroxylamines/therapeutic use; Internationality; Lactams/therapeutic use; Leucine/therapeutic use; Mice; National Institutes of Health (U.S.)/organization & administration; Nitriles/therapeutic use; Peptide Elongation Factor 1/antagonists & inhibitors; Peptides, Cyclic/pharmacology; Peptides, Cyclic/therapeutic use; Proline/therapeutic use; Protease Inhibitors/pharmacology; Protease Inhibitors/therapeutic use; RNA-Dependent RNA Polymerase/antagonists & inhibitors

Drug discovery; SARS-CoV-2; Therapeutics